One night of sleep deprivation causes the accumulation of a protein associated with Alzheimer’s Disease progression

There has been an emerging interest in sleep and its association with ?-amyloid burden as a risk factor for Alzheimer?s disease. Despite the evidence that acute sleep deprivation elevates ?-amyloid levels in mouse interstitial fluid and in human cerebrospinal fluid, not much is known about the impact of sleep deprivation on ?-amyloid burden in the human brain. Using positron emission tomography, here we show that acute sleep deprivation impacts ?-amyloid burden in brain regions that have been implicated in Alzheimer?s disease. Our observations provide preliminary evidence for the negative effect of sleep deprivation on ?-amyloid burden in the human brain. The effects of acute sleep deprivation on ?-amyloid (A?) clearance in the human brain have not been documented. Here we used PET and 18F-florbetaben to measure brain A? burden (ABB) in 20 healthy controls tested after a night of rested sleep (baseline) and after a night of sleep deprivation. We show that one night of sleep deprivation, relative to baseline, resulted in a significant increase in A? burden in the right hippocampus and thalamus. These increases were associated with mood worsening following sleep deprivation, but were not related to the genetic risk (APOE genotype) for Alzheimer?s disease. Additionally, baseline ABB in a range of subcortical regions and the precuneus was inversely associated with reported night sleep hours. APOE genotyping was also linked to subcortical ABB, suggesting that different Alzheimer?s disease risk factors might independently affect ABB in nearby brain regions. In summary, our findings show adverse effects of one-night sleep deprivation on brain ABB and expand on prior findings of higher A? accumulation with chronic less sleep.

About Robert Zinn

Robert Zinn, M.D., Ph.D. is a medical doctor, physician, and web entrepreneur, who, for over 15 years was employed by academic and research institutions and focused his clinical practices on very specialized patient populations, such as those with rare genetic diseases or rare cancers. He shares his knowledge through his website,

View all posts by Robert Zinn →